Parallel Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Parallel Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-96	Closed	-$899	–	3681
2025 Q2	$899	Sell	96 -236	-71%	-$2.6K	﹤0.01%	3217
2025 Q1	$4.08K	Sell	332 -29	-8%	-$409	﹤0.01%	2749
2024 Q4	$4.77K	Hold	361	–	–	﹤0.01%	2665
2024 Q3	$6.95K	Hold	361	–	–	﹤0.01%	2517
2024 Q2	$7.41K	Sell	361 -124	-26%	-$2.6K	﹤0.01%	2416
2024 Q1	$11.5K	Buy	485 +124	+34%	+$2.77K	﹤0.01%	2243
2023 Q4	$7.8K	Sell	361 -125	-26%	-$1.92K	﹤0.01%	2379
2023 Q3	$7.06K	Buy	+486	New	+$9.19K	﹤0.01%	2356
2022 Q4	–	Sell	-20	Closed	–	–	3510
2022 Q3	$0	Buy	20 +11	+122%	+$247	﹤0.01%	3473
2022 Q2	$0	Buy	+9	New	+$150	﹤0.01%	3336
2022 Q1	–	Sell	-13	Closed	–	–	3256
2021 Q4	$0	Buy	+13	New	+$240	﹤0.01%	3279

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Parallel Advisors's SNDX Position: Q3 2025 in Review

Parallel Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 96 shares — an estimated $899 sold.

Parallel Advisors first reported a position in SNDX in Q4 2021 and held it in 11 quarters. The position peaked at $11.5K in Q1 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

Parallel Advisors reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Parallel Advisors sold 96 Syndax Pharmaceuticals shares in Q3 2025, an estimated $899.
Parallel Advisors first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 11 quarters.
Parallel Advisors's Syndax Pharmaceuticals position peaked at $11.5K in Q1 2024.
227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Parallel Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.